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The structures of membrane receptors mediating rapid, nongenomic
actions of steroids have not been identified. We describe the cloning
of a cDNA from spotted seatrout ovaries encoding a protein that
satisfies the following seven criteria for its designation as a steroid
membrane receptor: plausible structure, tissue specificity, cellular
distribution, steroid binding, signal transduction, hormonal regula-
tion, and biological relevance. For plausible structure, computer
modeling predicts that the protein has seven transmembrane do-
mains, typical of G protein-coupled receptors. The mRNA (4.0 kb) is
only detected in the brain and reproductive tissues on Northern blots.
Antisera only detect the protein (40 kDa) in plasma membranes of
reproductive tissues. The recombinant protein produced in an Esch-
erichia coli expression system has a high affinity (Kd  30 nM),
saturable, displaceable, single binding site specific for progestins.
Progestins alter signal transduction pathways, activating mitogen-
activated protein kinase and inhibiting adenylyl cyclase, in a trans-
fected mammalian cell line. Inhibition of adenylyl cyclase is pertussis
toxin sensitive, suggesting the receptor may be coupled to an inhib-
itory G protein. Progestins and gonadotropin up-regulate both mRNA
and protein levels in seatrout ovaries. Changes in receptor abundance
in response to hormones and at various stages of oocyte develop-
ment, its probable coupling to an inhibitory G protein and inhibition
of progestin induction of oocyte maturation upon microinjection of
antisense oligonucleotides are consistent with the identity of the
receptor as an intermediary in oocyte maturation. These characteris-
tics suggest the fish protein is a membrane progestin receptor
mediating a ‘‘nonclassical’’ action of progestins to induce oocyte
maturation in fish.
Many physiological effects of steroid hormones are too rapidto be mediated by the classical genomic mechanism of
steroid action involving activation of nuclear steroid receptors
(1–3). Rapid, nongenomic steroid actions initiated on the cell
surface have been described in a wide variety of animal, tissue,
and cell models (4–8). Steroid membrane receptors character-
ized in plasma membrane fractions of many target tissues are the
likely intermediaries of these nonclassical steroid actions (6,
9–11). For example, extensive studies in our laboratory have
demonstrated that a progestin membrane receptor characterized
in spotted seatrout (Cynoscion nebulosus) ovaries mediates the
induction of oocyte meiotic maturation by the maturation-
inducing steroid, 17,20,21-trihydroxy-4-pregnen-3-one (20-S),
in this species (12–15). However, detailed knowledge of the
molecular structures and mechanisms of action of steroid mem-
brane receptors has eluded investigators, despite intensive re-
search efforts in many laboratories over several decades to purify
and sequence the receptor proteins (16–20). The minute quan-
tities of receptor proteins present in target tissues and major
losses of binding activity during solubilization and fractionation
have been insurmountable problems in receptor purification.
Therefore, we developed an alternative strategy, which involved
a combination of protein purification, antibody screening, and
molecular approaches, to clone the progestin membrane recep-
tor (mPR) from a spotted seatrout ovarian cDNA library (15).
Mice were immunized with a partially purified progestin mem-
brane receptor fraction containing a major protein band around
40 kDa obtained by DEAE chromatography of a solubilized
ovarian membrane extract (see Supporting Text and Fig. 8b,
which are published as supporting information on the PNAS web
site, www.pnas.org). The mouse splenocytes were fused, and
hybrid cultures established. Monoclonal antibodies that recog-
nized ovarian plasma membrane proteins in the 25- to 100-kDa
range were screened for receptor recognition (specific progestin
binding) by using a double-antibody receptor capture assay we
developed for binding proteins, such as steroid membrane
receptors, with rapid rates of dissociation (15). Positive antibod-
ies were subsequently used to screen a seatrout ovarian expres-
sion library. This paper describes a gene and its protein identified
by this approach with the characteristics of an mPR.
Materials and Methods
Cloning and Expression of a Putative mPR. Total RNA was extracted
from seatrout ovarian tissue (2.1 g) by using 30 ml of TRIzol
extraction reagent (Life Technologies, Rockville, MD), and mRNA
was purified with magnetic oligo(dT) particles by using Straight A’s
mRNA Isolation System (Novagen). First- and second-strand
cDNAs were synthesized from the polyadenylated mRNA by using
a TimeSaver cDNA Synthesis Kit (Amersham Pharmacia) and
linked to adaptors containing an EcoRI linker and an internal NotI
site. A seatrout ovarian cDNA library was constructed after ligation
of synthesized cDNAs into EcoRI sites of ZAP II vectors and
packaging of ligated ZAP vectors (Stratagene). Expressed fusion
proteins from 300,000 phages were screened with mouse monoclo-
nal antibodies (obtained previously) and a goat anti-mouse pi-
coBlue immunoscreening kit (Stratagene). Positive clones were
subjected to three additional rounds of screening before excision of
pBluescript II SK () plasmid vector from ZAP II phage and
purification of selected plasmids for further analysis. Sequencing
was performed for both strands of the selected cDNA clones by
using an automated DNA sequencer (model 310, Perkin–Elmer).
Computer sequence analysis was carried out by using the Wisconsin
Package GCG V.9.1 programs (Genetics Computer Group, Madison,
WI) on a UNIX platform (Sun 5.3, SUN Microsystems, Mountain
View, CA) and MACVECTOR V.6.1 (Oxford). A homologous search
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of sequences was carried out by using BLAST (National Center for
Biotechnology Information, at http://www.ncbi.nlm.nih.gov/
BLAST/).
Northern Blot Analysis. Expression of the putative mPR gene in
seatrout tissues was examined with Northern hybridization by
using total RNA and a Northern Max Kit (Ambion, Austin, TX)
following the procedures described in the paper by Zhu et al. in
this issue of PNAS (21).
Membrane Preparation, Solubilization, and Receptor Binding Assays.
Membrane fractions of ovarian tissue or human MDA-MB-231
cells were obtained following procedures described (12) with few
modifications. An additional centrifugation step of 500  g for
5 min was included to remove any remaining nuclear material.
The resulting supernatant was centrifuged at 20,000  g for 20
min to obtain the plasma membrane fraction and twice at
150,000  g for 1 h to produce a cytosolic fraction. For Western
blot analyses, the plasma membrane was further purified by
centrifuging the pellet three times with a sucrose pad (1.2 M
sucrose) at 6,500  g for 45 min. Treatment of resuspended
membrane with 12 mM Triton X-100 in 4 vol of HA buffer (25
mM Hepes, 10 mM NaCl, 1 mM dithioerythritol, pH 7.8) for 30
min, followed by removal of detergent with polystyrene adsor-
bents (2:1 vol:wt; Bio-Rad SM-2) for 2 h and subsequent removal
of the adsorbents by filtration (G-8 filter, Fisher), resulted in
recovery of 70–80% of the original specific binding in the
solubilized fraction. Solubilized receptor incubation conditions
were similar to those used for the intact membrane preparation
(12). The incubation (at 4°C) was terminated by adding 1 ml of
ice-cold dextran-coated charcoal suspension (0.1 g of dextran
T-70 and 1 g of charcoal per 100 ml of HA buffer); the reaction
mixture was incubated on ice for 5 min to absorb free steroid,
followed by centrifugation at 3,200  g for 10 min at 4°C.
Western Blot Analysis and Immunocytochemistry. Specific, high-titer
rabbit polyclonal antibodies were generated against synthetic 20-
oligo peptides derived from the N-terminal domain (stmPRpAb1)
and second extracellular loop (stmPRpAb2) of the putative mPR
linked to keyhole limpet hemocyanin after six intradermal injec-
tions (50–100 mg per injection in Freund’s adjuvant). For Western
blot analysis, solubilized membrane proteins were resolved in
SDS12% PAGE gels and transferred to a nitrocellulose mem-
brane. The membrane was blocked with 5% nonfat milk in TBST
(50 mM Tris100 mM NaCl0.1% Tween 20, pH 7.4) for 1 h,
incubated with antibody overnight, followed by four 5-min TBST
washes, incubated for 1 h at 23°C with horseradish peroxidase
conjugated to goat anti-rabbit antibody (Cell Signaling, Beverly,
MA), and finally washed three times for 15 min with TBST. Blots
then were treated with enhanced chemiluminescence (Amersham
Pharmacia) and exposed to x-ray film. Representative fixed ovarian
sections (fixed in 10% buffered formalin for several days), contain-
ing fully grown follicles, were incubated with primary antiserum
(stmPRpAb1) for 18 h at 4°C before labeling by the ABC method
(Vector Laboratories, Burlingame, CA).
Expression of Recombinant Protein in Escherichia coli BL21(DE3) Cells.
The putative mPR coding region was amplified by PCR from a
full-length cDNA plasmid clone following protocols described in
the paper by Zhu et al. (21). PCR products were purified and
ligated into a pET-27b expression vector (Novagen), which was
then transformed into BL21(DE3) E. coli cells. Positive clones
were purified and sequenced. Plasmids without an insert and
with a reversed mPR sequence insert were used as controls.
Expression of recombinant protein was induced with isopropyl
-D-thiogalactoside (IPTG) at 25°C. Soluble recombinant pro-
teins were extracted from whole-cell lysates, and aliquots (250g
of protein) were analyzed for progestin binding, as described.
Progestin Regulation of Signal Transduction Pathways in Transfected
MDA-MB-231 Cells. The putative mPR coding region was amplified
by PCR and inserted into a PBK-CMV expression vector (Strat-
agene). Correct insertion was verified by DNA sequencing. Human
MDA-MB-231 breast carcinoma cells (American Type Culture
Collection) were transfected with either mPR cDNA, an empty
carrier vector, or a vector containing reversed mPR insert by using
Lipofectamine (Life Technologies) following manufacturer’s sug-
gestions and grown to 80% confluence for 2–3 days in media
containing 10% (volvol) charcoal-stripped FBS.
cAMP analysis. Transfected MDA-MB-231 cells were washed three
times with PBS buffer. Serum-free medium was added and the cells
were preincubated with or without pertussis toxin for 30 min at 37°C
before stimulation with steroids for 5 min. Cells were harvested and
frozen at 70°C until analysis. cAMP concentrations were mea-
sured in cytosolic fractions according to the manufacturer’s instruc-
tions (Biomedical Technologies, Stoughton, MA).
Mitogen-activated protein (MAP) kinase analysis. Procedures described
by Filardo et al. (22) were followed for selection and culture of
cells. Cells were subsequently cultured in serum-free media for
3 days to reduce basal extracellular signal-regulated kinase
(Erk)1 and Erk2 activities to minimum levels. Cells were incu-
bated with steroids or recombinant human epidermal growth
factor (EGF; Upstate Biotechnology, Lake Placid, NY), a
positive control for MAP kinase activation, for 5–15 min. Cells
then were harvested and lysed, and 20 g of cytosolic protein
were separated by SDSPAGE and transferred to a nitrocellu-
lose membrane. Activation of MAP kinase was assessed by
Western blot analysis by using both phosphorylated Erk1 and
Erk2 and phosphorylation-independent (i.e., total) Erk1 and
Erk2 antibodies (Cell Signaling).
Microinjection of Zebrafish Oocytes with Antisense Oligonucleotides
to Zebrafish mPR. In three separate experiments, midvitellogenic
follicle-enclosed oocytes with diameters of 450–500 m were
microinjected with1 nl (2.5% of total oocyte volume) of either
morpholino or phosphorothioate antisense oligonucleotides to the
homologous mPR cloned from zebrafish (final concentration 25
M), or their respective control oligonucleotides dissolved in 60%
Leibovitz L-15 made with ultra-pure water (concentration  1
mM), or L-15 alone (controls). Follicles (10–15 follicles per 0.1 ml)
were incubated at 26°C for 5–6 h in the presence of gonadotropin
(hCG, 20 units per ml) to induce oocyte maturational competence
(OMC; ref. 23) and incubated for a further 10 h in fresh medium
containing 50 nM of the maturation-inducing steroid, 17,20-
dihydroxy-4-pregnen-3-one (17,20-P). Oocytes were scored at the
end of the incubation for disappearance of the nucleus and disso-
lution of yolk in the ooplasm, easily identifiable markers of oocyte
maturation.
Results
Cloning and Sequence Analysis of a Putative mPR. Four positive
monoclonal antibodies that bound ovarian protein preparations
with specific 20-S binding activity were identified with the receptor
capture assay (see Supporting Text and Table 1, which are published
as supporting information on the PNAS web site; ref. 15). One
cDNA clone was isolated after screening of a seatrout ovarian
expression cDNA library by using one of the monoclonal antibodies
(PR10-1). The 1.7-kb cDNA sequence has an ORF of 1,059 bp
encoding a protein of 352 amino acids with an estimated molecular
mass of 40,585 Da (GenBank accession no. AF262028). Compar-
ison of the cDNA sequence with available sequences in the Gen-
Bank database suggests it encodes a previously uncharacterized
protein. Computer analyses [DAS, HMMTOP, PREDICT PROTEIN,
SOSUI (24), TMHMM, TMPRED, TOPPRED2] of the deduced amino
acid sequence consistently predicted that the protein is located in
the plasma membrane and has seven transmembrane domains,
which is characteristic of G protein-coupled membrane receptors.
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A representative hydrophilicity plot is shown (Fig. 1a). The protein
is rich in cysteine (13 residues, 3.68%) and leucine (41 residues,
11.6%). The cysteines could form bridges both within and among
the receptor molecules. One N-linked glycosylation site at the
N-terminal end and multiple phosphorylation sites are predicted by
NETPHOS analysis (Fig. 1b; ref. 25).
Tissue Distribution of mRNA and Cellular Localization of the Putative
mPR. Northern blot analysis showed a major band 4 kb and a
minor band at 1.7 kb in the ovary (Fig. 2a), as well as 4-kb bands
in the brain, testis, and pituitary (Fig. 2a). No detectable signals
were obtained in heart, kidney, liver, spleen, intestine, gill, and
muscle (Fig. 2a), suggesting the receptor gene is expressed only in
reproductive and neuroendocrine tissues. A single immunoreactive
band 40 kDa was detected by Western blot analysis by using
monoclonal antibody PR10-1 in the solubilized ovarian membrane
fraction and in the purified membrane fraction 1 used to generate
the monoclonal antibodies, whereas no immunoreactivity was de-
tected in the cytosolic fraction (Fig. 2b). A protein band with a
molecular mass40 kDa was also detected in a solubilized oocyte
membrane (OM) fraction as well as in the membranes of denuded
oocytes (DO) by Western blot analysis using polyclonal antibody
stmPRAb1 (Fig. 2c). A slightly higher molecular weight band was
detected in sperm membranes (SM), which possibly reflects a
different posttranslational modification. No immunoreaction was
obtained in cytosolic fractions of oocytes or the membranes of
follicle cells (Fig. 2c). Identical results (not shown) were obtained
with the stmPRAb2 antibody. These studies show that the putative
mPR is localized on oocyte and sperm plasma membranes, sites
where specific mPRs have been characterized (12, 26).
Strong immunoreactivity was observed only on the oocyte
surface layer containing the plasma membrane of a represen-
tative fully grown seatrout oocyte under high power magnifica-
tion (Fig. 2d). No specific immunoreactive staining was detected
in follicle cells or in the cytoplasm of the oocyte. These results
clearly demonstrate the oocyte plasma membrane localization of
the receptor in seatrout.
Steroid Binding of Putative mPR Produced in E. coli. An essential
criterion to meet is that steroid binding to the recombinant protein
should be characteristic of steroid membrane receptors. The re-
Fig. 1. Structural analysis of deduced amino acid sequence of putative mPR gene. (a) Hydrophilicity profile according to GES method (GoldmanEngelman
Steitz, 1986). (b) Schematic diagram of encoded protein showing extracellular (gray), seven-transmembrane (solid black), and cytoplasmic (clear) domains
predicted by several programs. Vertical lines indicate potential phosphorylation sites., potential N-linked glycosylation site. Numbers above: amino acids from
N-terminal end; numbers below: number of amino acids in each domain. Hatched boxes: peptide sequences used to generate polyclonal antibodies.
Fig. 2. Tissue distribution and cellular localization of putative mPR. (a)
Northern blot analysis showing mRNA expression in ovarian (O, gel load-
ing: 1g) and other tissues (gel loading: 5g); B, brain; T, testis; P, pituitary;
H, heart; K, kidney; L, liver; S, stomach; I, intestine; G, gill; M, muscle. (b)
Western blot analysis of solubilized ovarian membrane proteins using
monoclonal antibody PR10-1. I, plasma membrane; II, cytosol; III, partially
purified membrane fraction used to generate monoclonal antibodies. (c)
Cellular localization of receptor by Western blot analysis using
stmPRpAb1 antibody (gel loading: 10 g). OC, oocyte cytosol; OM, oocyte
membrane; Folli., follicle cell membrane; DO, denuded oocyte plasma
membrane; SM, sperm membrane; I, recombinant protein induced by IPTG
in E. coli; UI, noninduced E. coli protein; K4, membrane proteins from
mPR-transfected MDA-MB-231 cells; K3, control cells transfected with
vector containing reverse insert; CMV, control cells transfected with empty
carrier vector. The following lanes were probed with PR10-1 antibody: K4
PM, plasma membrane from mPR transfected MDA-MB-231 cells; K4 Cyt,
cytosol from mPR transfected cells. (d) Immunocytochemical localization of
mPR receptor protein in a mature seatrout follicle containing a stage IV
oocyte using stmPRpAb1 antibody. Folli., follicle cells; PM, oocyte plasma
membrane; Cyt, oocyte cytoplasm. (Magnification: 1 cm  20 m.)
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ceptor protein should demonstrate high affinity, saturable and
displaceable binding that is specific for steroids, and display rapid
dissociation and association kinetics. The coding region of the
receptor was inserted into a pET-27b expression vector, and soluble
recombinant protein was produced in BL21 E. coli cells (lane I in
Fig. 2c). Saturable, specific progesterone binding was obtained with
the recombinant protein (Fig. 3a), whereas no specific progesterone
binding was observed with control proteins expressed by E. coli
without IPTG induction or transformed with an empty vector (Fig.
3a). Saturation analysis confirmed progestin binding to the recom-
binant bacterial protein was saturable (Bmax  0.49 nM, Fig. 3b).
Scatchard analysis showed the presence of a single class of high-
affinity binding sites (Kd 30 nM, Fig. 3b). Progestin binding to the
receptor was readily displaceable, with60% of [3H]progesterone
exchanged within 10 min (Fig. 3c). The kinetics of association and
dissociation were rapid, with t1/2s of 7.8 and 2.2 min, respectively
(Fig. 3c), which are typical for steroid membrane receptors (15).
Steroid competition studies showed binding was highly specific for
progesterone and 17-hydroxyprogesterone (Fig. 3d). No displace-
ment of [3H]progesterone was observed with estradiol-17, corti-
sol, and 20-S, whereas 20-hydroxyprogesterone, testosterone,
17,20-dihydroxy-4-pregnen-3-one (17,20-P) and 11-deoxycorti-
sol showed displacement at 10- to 100-fold higher concentrations
(Fig. 3d).
Alteration of Intracellular Signal Transduction Pathways. To deter-
mine whether progestin binding to the putative mPR causes
rapid activation of intracellular signaling pathways, the cDNA
coding region was inserted into a mammalian expression vector,
PBK-CMV, and stably transfected into MDA-MB-231 breast
cancer cells. The receptor protein was localized in the plasma
membranes of the transfected cells (lane K4 PM in Fig. 2c) and
was not detected in the cytosolic fraction (Fig. 2c, lane K4 Cyt).
The presence of two higher molecular weight immunoreactive
bands in the membrane fraction may be the result of aggregation
of the receptor protein, because SDS-resistant oligomers are
commonly observed with G protein-coupled receptors (GPCR;
ref. 27). Production of cAMP was significantly reduced within 5
min of progestin addition (20-S) in the transfected cells and was
partially recovered by 30 min (results not shown). Subsequent
experiments showed this inhibitory effect of progesterone and
20-S was partially blocked when the cells were pretreated with
pertussis toxin, a specific inhibitor for Gi/o proteins (Fig. 4a). In
contrast, these progestins did not exert an inhibitory effect in
control cells transfected with a carrier vector or a reversed
vector. Erk1 and Erk2 were activated within 5 min after stimu-
lation by progesterone and 20-S (Fig. 4b), whereas no activation
of Erk1 and Erk2 was observed in control cells transfected with
an empty carrier vector or a control vector containing a reversed
insert (Fig. 4b). Activation of MAP kinase by progesterone and
20-S was rapid and transient (Fig. 4c). Significant activation
occurred 5 min after addition of the hormones, with subsequent
declines in phosphorylated Erk1Erk2 protein after 15 min of
exposure (Fig. 4c). MAP kinase activation by the progestins was
also dose-dependent over the range of 10–1,000 nM.
In addition to demonstrating activation of intracellular signaling
pathways, the cAMP experiments showing a decrease in intracel-
lular cAMP levels soon after addition of the progestin hormones to
the transfected cells suggest the receptor activates an inhibitory G
protein. Subsequent experiments demonstrating that the inhibitory
effect was reversed by preincubation with an inhibitor of Gi/o
proteins, pertussis toxin, are also consistent with this suggestion.
Fig. 3. Steroid binding characteristics of recombinant mPR protein produced in
E. coli. (a) Representative plots of specific [3H]progesterone binding to protein
produced with a cDNA-inserted vector with (F) or without () IPTG induction, or
an empty carrier vector (, controls). (b) Scatchard analysis of specific [3H]pro-
gesterone binding. (c) Time course of association and dissociation of specific
[3H]progesterone binding. (d) Competition curves of steroid binding expressed as
a percentage of maximum specific [3H]progesterone binding [concentration:
[3H]progesterone, 10 nM, specific activity; 65 Cimmol (1 Ci37 GBq); Amersham
Pharmacia]; E, progesterone; , 17-hydroxyprogesterone; F, 20-hydroxypro-
gesterone; ‚, 20-S;, testosterone;, 17,20-dihydroxy-4-pregnen-3-one; ƒ,
11-deoxycortisol;, estradiol-17; , cortisol.
Fig. 4. Inhibition of cAMP production (a) and activation of MAP kinase signal-
ing pathway (b and c) in response to progestin hormones in MDA-MB-231 cells
stably transfected with putative mPR cDNA (means SEM, n 4; *, P 0.05). (a)
Cells were preexposed to activated pertussis toxin (PTX) or inactive pertussis toxin
(inPTX) for 30 min at 37°C before incubation with 20-S or progesterone for 5
min. (b) MAP kinase activity (shown as increase in phospho-Erk12) in cells
transfected with vector containing mPR insert (white bar), controls containing
reversed insert (shaded bar) or vector alone (black bar) after a 5-min stimulation
with 1 M 20-S or progesterone (P4). C, untreated control; EGF, human epider-
mal growth factor (1 M, positive control). (c) Time- and dose-dependent acti-
vationofMAPkinase(gel loading:20gper lane) intransfectedcells treatedwith
20-S, P4, estradiol-17 (E2), or testosterone (T).
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Hormonal Regulation. Both the putative membrane receptor
mRNA and protein were up-regulated in ovarian tissues after
incubation with 20-S. Receptor mRNA and protein levels were
significantly increased in ovarian tissues incubated with 20-S
(290 nM, Fig. 5) for 6–8 h. The mRNA and protein levels
subsequently decreased after an 8- to 12-h incubation. (Fig. 5).
No changes in receptor mRNA or protein expression were
observed in control tissues incubated without hormones (data
not shown). hCG treatment (15 units per ml of hCG) also caused
an up-regulation of receptor protein levels (Fig. 6b).
Biological Relevance. Receptor protein levels in fish captured on
their spawning ground were lower in fully grown oocytes compared
with those at a later stage of maturation undergoing germinal
vesicle breakdown (GVBD, threefold increase) and were lowest in
ovulated oocytes (Fig. 6a). A similar pattern of receptor changes
was observed during oocyte maturation in laboratory studies. A
rapid increase in receptor levels occurred in fully grown (stage IV)
oocytes during hCG-induced oocyte maturation (GVM and
GVBD), followed by a dramatic decline in receptor levels in
ovulated oocytes (Fig. 6 b and c). Receptor protein levels were low
in the smallest early stage vitellogenic oocytes and showed a
size-dependent increase in later vitellogenic stage oocytes (Fig. 6 b
and c). These results further indicate an intimate relationship
between the putative mPR and oocyte maturation.
Antisense studies could not be performed with seatrout oocytes
because of their fragility. Therefore, the homologous mPR gene in
zebrafish (mPR; ref. 21) was cloned for antisense microinjection
studies because their oocytes tolerate these procedures. The nu-
cleotide sequence of the zebrafish cDNA was 73% identical with
that of seatrout, whereas the deduced amino acid sequence dis-
played 80% identity. Microinjection of zebrafish oocytes with
zebrafish mPR (21) antisense consistently blocked maturation of
oocytes in vitro in response to the maturation-inducing steroid in
zebrafish, 17,20-P. The percentage of oocytes that matured was
significantly lower in the mPR antisense groups (6.5%, phospho-
rothioated antisense in Fig. 7a; 5.8%, morpholino antisense in Fig.
7b) than in the control groups (38.5%, phosphorothioated sense in
Fig. 7a; 51.4%, morpholino mis-antisense in Fig. 7b). These results
from the antisense experiments provide more direct evidence of an
involvement of the putative mPR in progestin induction of oocyte
maturation in teleosts.
Discussion
These results provide clear evidence that the hitherto unknown
gene isolated from spotted seatrout ovaries encodes a steroid
membrane receptor. The following seven criteria were met for its
designation as a steroid membrane receptor: structural plausi-
bility, tissue specificity, plasma membrane localization, charac-
teristic steroid binding, activation of signal transduction path-
ways, hormonal regulation, and biological relevance. In
particular, the presence of high affinity, saturable, displaceable,
single binding sites specific for a single class of steroids on the
recombinant protein are defining characteristics of steroid re-
ceptors. To our knowledge, this is the first gene and its protein
unrelated to steroid nuclear receptors that has been shown to
fulfill all of the criteria for steroid receptor designation.
In addition, substantial evidence was obtained that the receptor
mediates progestin induction of oocyte meiotic maturation in
spotted seatrout. Firstly, the tissue and cellular localization of the
protein and mRNA are consistent with its proposed function as the
membrane receptor regulating gamete maturation in this species.
The mRNA is only detected in reproductive endocrine and brain
tissues, and the protein is localized on the plasma membrane of
oocytes and sperm, where progestin membrane receptors have been
fully characterized in seatrout (12, 15, 26). Moreover, the patterns
Fig. 5. Time course of changes in putative mPR mRNA (a and b) and protein
levels (c and d) in ovarian fragments after in vitro treatment with 300 nM
20-S, relative to control (0 h) values (mean  SEM, n  4; *, P  0.05).
(a) Representative Northern blot (gel loading: 1 g). (Lower) Putative mPR
mRNA. (Upper) Corresponding -actin mRNA. (b) Relative levels of mPR
mRNA. (c) Representative Western blot analyses using PR10-1 and stmPRAb1
antibodies (gel loading: 10 g). (d) Relative levels of mPR protein.
Fig. 6. Changes in putative mPR protein levels in oocytes at various stages of
development and final maturation detected by Western blot analysis with
stmPRAb1 antibody (gel loading: membrane proteins from five oocytes per
lane). (a) In wild fish captured on their spawning grounds. (b) After incubation
in vitro in the presence or absence of hCG. I, vitellogenic oocyte, 200–300 m
(diameter); II, 300–375 m; III, 375–440 m; IV, full-grown oocyte, 430–500
m; GVM, germinal vesicle migration stage of final maturation; GVBD, ger-
minal vesicle breakdown stage of final maturation. (c) mPR protein levels
expressed relative to stage I oocyte values.
Fig. 7. Effects of microinjection of zebrafish oocytes with zebrafish antisense
oligonucleotides on their subsequent maturation in response to 17,20-P
(mean SEM, n 4; *, P 0.05). (a) Phosphorothioate antisense experiment.
CTL, control uninjected oocytes; MED, injected with media alone; As, zebra-
fish mPR -antisense; S, mPR -sense; mAS, mPR -mis-antisense. (b) Morpho-
lino antisense experiment.
Zhu et al. PNAS  March 4, 2003  vol. 100  no. 5  2235
BI
O
CH
EM
IS
TR
Y
SE
E
CO
M
M
EN
TA
RY
of protein changes suggest an involvement of the receptor in oocyte
maturation. The dramatic increase in receptor protein levels in
oocytes undergoing meiotic maturation and the subsequent de-
crease in protein levels in ovulated oocytes a few hours later closely
parallel the changes in progestin membrane receptor-binding ac-
tivity observed previously in seatrout oocytes during this period (12,
13). Earlier structureactivity studies had established that the
progestin membrane receptor is an intermediary in the maturation-
inducing steroid initiation of oocyte maturation in this species (14).
In addition, the finding that the protein is up-regulated by hCG
supports a physiological role for the receptor in oocyte maturation.
Both the receptor protein and its mRNA are significantly elevated
in seatrout ovaries after 8-h incubation with 15 units hCG, similar
to the time-course (6–9 h) for hCG up-regulation of progestin
membrane receptor binding activity (13). Up-regulation of the
progestin membrane receptor is associated with the development of
the ability of oocytes to become responsive to progestins (OMC)
and complete meiotic maturation (13). Interestingly, hCG-induced
increases in receptor protein levels in the present study also
coincided with the development of OMC. Finally, the up-regulation
of the receptor mRNA by 20-S suggests a potential role for the
nuclear progestin receptor in the development of OMC, which
could also partially explain some recent results obtained with
Xenopus (discussed in ref. 15).
Direct evidence for a role of the mPR in the induction of
oocyte maturation was obtained from microinjection studies
with zebrafish oocytes. It was clearly demonstrated that micro-
injection with two types of mPR antisense oligonucleotides
directed against the zebrafish homolog (zebrafish ; ref. 21)
prevented oocyte maturation in response to the progestin.
However, injections with control oligonucleotides did not influ-
ence oocyte maturation. Finally, the finding that the seatrout
progestin receptor activates a pertussis toxin–sensitive inhibitory
G protein is entirely consistent with its proposed role as the
receptor mediating progestin induction of oocyte maturation in
fishes. It is well established that progestin induction of oocyte
maturation in fish and amphibians involves a decrease in intra-
cellular cAMP (15, 20, 28). Moreover, we have shown that
microinjection of pertussis toxin blocks maturation of seatrout
oocytes as well as those in a closely related perciform species,
Atlantic croaker, in response to the hormone (15). A pertussis
toxin-sensitive G protein has also been implicated in the pro-
gestin induction of oocyte maturation in rainbow trout (28).
The results of progestin specificity studies in the different
expression systems are somewhat equivocal. The fact that both
20-S and progesterone alter the activities of adenylyl cyclase
and MAP kinase in human breast cancer cells transfected with
the receptor cDNA indicates it recognizes both progestins,
whereas the recombinant protein produced in E. coli only binds
progesterone. Taken together, these findings suggest deficiencies
in the E. coli expression system for receptor protein production,
possibly related to the lack of glycosylation of the recombinant
protein or other posttranslational modifications.
Progestin induction of oocyte maturation is inhibited in the
presence of pertussis toxin, suggesting that the receptor mediating
oocyte maturation activates an inhibitory G protein (15, 28) and,
therefore, may be a GPCR. The structural analysis data for the
receptor protein are in accordance with this suggestion. The
presence of seven transmembrane domains in the receptor protein
suggests it may be a GPCR. Moreover, the molecular mass of the
progestin receptor protein (40 kDa) is within the expected range for
GPCRs (29). Finally, the signal transduction experiments indicate
the receptor activates an inhibitory G protein, which also suggests
it may be a GPCR. If additional research confirms that the seatrout
and zebrafish progestin membrane receptor proteins we have
discovered are GPCRs, they are not closely related to the other
GPCR subclasses identified to date (30) and most likely represent
a separate subclass of this receptor type. Recent studies suggest
widespread involvement of G proteins in nonclassical steroid ac-
tions (31–33). Inhibitory G proteins have also been implicated in the
signal transduction of rapid, nongenomic glucocorticoid, estrogen,
and androgen actions in a variety of cell types (34–36). Future
investigations on the structural homology of the GPCRs mediating
these nonprogestin steroid actions with the seatrout progestin
receptor should provide insights into the evolution of this type of
steroid receptor. GPCRs represent one of the largest and possibly
most ancient classes of receptors, responding to a diverse array of
signaling molecules (37). The preliminary finding that steroids, a
major class of signaling molecules, may also act via this mechanism,
provides a further indication of the ubiquity of this signaling system
and its probable ancient origins (38).
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